This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Apr;18(4):205-206.

doi: 10.1038/s41581-022-00544-5.

Belzutifan: a novel therapy for von Hippel-Lindau disease

Jingcheng Zhou^{1

2}, Kan Gong^{3

4}

Affiliations

Affiliations

¹ Department of Urology, Peking University First Hospital, Beijing, China.
² Institute of Urology, Peking University, Beijing, China.
³ Department of Urology, Peking University First Hospital, Beijing, China. gongkan_pku@126.com.
⁴ Institute of Urology, Peking University, Beijing, China. gongkan_pku@126.com.

PMID: 35132216
DOI: 10.1038/s41581-022-00544-5

Comment

Belzutifan: a novel therapy for von Hippel-Lindau disease

Jingcheng Zhou et al. Nat Rev Nephrol. 2022 Apr.

. 2022 Apr;18(4):205-206.

doi: 10.1038/s41581-022-00544-5.

Authors

Jingcheng Zhou^{1

2}, Kan Gong^{3

4}

Affiliations

¹ Department of Urology, Peking University First Hospital, Beijing, China.
² Institute of Urology, Peking University, Beijing, China.
³ Department of Urology, Peking University First Hospital, Beijing, China. gongkan_pku@126.com.
⁴ Institute of Urology, Peking University, Beijing, China. gongkan_pku@126.com.

PMID: 35132216
DOI: 10.1038/s41581-022-00544-5

No abstract available

PubMed Disclaimer

Comment on

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Jonasch E, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. N Engl J Med. 2021. PMID: 34818478 Free PMC article. Clinical Trial.

Similar articles

Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
Curry L, Soleimani M. Curry L, et al. Future Oncol. 2024;20(18):1251-1266. doi: 10.2217/fon-2023-0679. Epub 2024 Apr 19. Future Oncol. 2024. PMID: 38639572 Free PMC article. Review.
Re: Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Bensalah K, Khene ZE, Massard C. Bensalah K, et al. Eur Urol. 2022 May;81(5):545-546. doi: 10.1016/j.eururo.2022.01.014. Epub 2022 Jan 31. Eur Urol. 2022. PMID: 35094899 No abstract available.
First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland.
Peres T, Aeppli S, Fischer S, Hundsberger T, Rothermundt C. Peres T, et al. Curr Oncol. 2025 Jan 26;32(2):64. doi: 10.3390/curroncol32020064. Curr Oncol. 2025. PMID: 39996864 Free PMC article.
Belzutifan: A Narrative Drug Review.
Visweswaran V, Pavithran K. Visweswaran V, et al. Curr Drug Res Rev. 2022;14(2):88-95. doi: 10.2174/2589977514666220401094724. Curr Drug Res Rev. 2022. PMID: 35366789 Review.
Pancreatic metastases from renal cell carcinoma in von Hippel-Lindau disease.
Chambers TP, Fishman EK, Hruban RH. Chambers TP, et al. Clin Imaging. 1997 Jan-Feb;21(1):40-2. doi: 10.1016/0899-7071(95)00066-6. Clin Imaging. 1997. PMID: 9117930

See all similar articles

Cited by

Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
Curry L, Soleimani M. Curry L, et al. Future Oncol. 2024;20(18):1251-1266. doi: 10.2217/fon-2023-0679. Epub 2024 Apr 19. Future Oncol. 2024. PMID: 38639572 Free PMC article. Review.
Hypoxic stress and hypoxia-inducible factors in leukemias.
Magliulo D, Bernardi R. Magliulo D, et al. Front Oncol. 2022 Aug 18;12:973978. doi: 10.3389/fonc.2022.973978. eCollection 2022. Front Oncol. 2022. PMID: 36059690 Free PMC article. Review.
VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function.
Tong L, Tay AHM, Cui W, Liu Y, Su Y, Lyu J, Hoedemakers L, Yang Y, Ehnman M, Seliger B, Nordlund P, Haglund de Flon F, Neo SY, Lundqvist A. Tong L, et al. Cancer Immunol Immunother. 2025 Jul 30;74(9):278. doi: 10.1007/s00262-025-04132-x. Cancer Immunol Immunother. 2025. PMID: 40736709 Free PMC article.
RP11-367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial-mesenchymal transition.
Shao IH, Peng PH, Wu HH, Chen JL, Lai JC, Chang JS, Wu HT, Wu KJ, Pang ST, Hsu KW. Shao IH, et al. Cancer Med. 2023 Apr;12(8):9788-9801. doi: 10.1002/cam4.5723. Epub 2023 Feb 27. Cancer Med. 2023. PMID: 36847128 Free PMC article.
Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment.
Kim I, Choi S, Yoo S, Lee M, Kim IS. Kim I, et al. Cancers (Basel). 2022 Jul 7;14(14):3321. doi: 10.3390/cancers14143321. Cancers (Basel). 2022. PMID: 35884382 Free PMC article. Review.

See all "Cited by" articles

References

1. Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706–720 (2019). - DOI
1. Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N. Engl. J. Med. 385, 2036–2046 (2021). - DOI
1. Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673–682 (2002). - DOI
1. Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994). - DOI
1. Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. Structure of the VHL–ElonginC–ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455–461 (1999). - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information